The international leader in the production of containers for pharmaceutical use has signed a five-year agreement with IMEM-CNR to promote materials research
The COVID-19 pandemic and subsequent search for a vaccine have further highlighted the importance of glass containers in the drug supply chain, both from the point of view of performance and compatibility with new formulations.
As a result, the company has opened a new Glass Research Center at the headquarters of the Institute of Materials for Electronics and Magnetism (IMEM) - National Research Council (CNR), a reference point for national and international research in materials science.
In the new laboratories, Bormioli Pharma will conduct sophisticated analyses on the chemico-physical characteristics of its glass bottles and will promote research programs to identify alternative formulations and special surface treatments.
"With this project, we aim to create a center of excellence for innovation in glass containers for drugs with high therapeutic value", said Andrea Lodetti, CEO of Bormioli Pharma. "We will thus be able to reverse the paradigm in which the packaging supplier intervenes only at the end of the development process of new formulations, providing our contribution from the earliest stages of clinical trials".
In the coming months, Bormioli Pharma and CNR will also fund a PhD grant for the development of a new generation of glass bottles, capable of offering chemical neutrality, shock absorption and assembly line flow characteristics superior to any packaging solution on the market today.